Back to results
US 2022/0016154 A1Published application
Treatment of neuronal mosaicism in dementia
AssigneeCrownview Medical Group, Inc.
InventorMark Melden
Life of this patent
Estimating the term…
Abstract
A method for the use of at least one reverse transcriptase inhibitor, that when administered in a safe and effective amount, ameliorate at least one of the formation, maintenance, or expression of excessive neuronal mosaicism, and therefore decrease or block neurogenic mechanisms underlying or associated with dementia.
Claims10
A method, comprising:
- identifying a patient as having dementia, and
- administering a therapeutically effective amount of reverse transcriptase inhibitor, whereby the reverse transcriptase inhibitor interrupts a neurogenic pathway associated with neuronal mosaicism.
Dependencies are inferred from the claim text.